OLEG ZAUZOLKOV

Dr. OLEG ZAUZOLKOV

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2026 in Koloproktologia
Verified
Journal Article
Open access
PDF file
OZOLEG ZAUZOLKOV
OLEG ZAUZOLKOV
MLMarina A. Lyadova
Marina A. Lyadova
Vladimir K. LyadovVladimir K. Lyadov
Vladimir K. Lyadov
DFDenis Fedorinov
Denis Fedorinov
EKEvgeniya A. Kulikova
Evgeniya A. Kulikova
JMJulia S. Mansurova
Julia S. Mansurova
AIM : to assess the efficacy of immunotherapy in patients with locally advanced CRC and MSI. PATIENTS AND METHODS: three clinical cases of patients with locally advanced colorectal cancer and microsatellite instability are presented. RESULTS: all three patients experienced major clinical and radiological improvement shortly after the start of ICI treatment. The third patient developed a 2nd degree immune-mediated pneumonitis that necessitated hormonal therapy and ICI termination. This patient got a subsequent laparoscopic right colectomy which proved complete pathomorphologic response. Recurrent-free survival since the beginning of ICI treatment is 54, 30 and 18 months, respectively. CONCLUSION: patients with locally advanced CRC and MSI even in case of unresectability may benefit greatly after immunotherapy. This makes it crucial to evaluate the presence of MSI in this patients.

Verified
Journal Article
Open access
PDF file
GZGalina Sergeevna Zakharova
Galina Sergeevna Zakharova
OZOLEG ZAUZOLKOV
OLEG ZAUZOLKOV
AKAnna Khristichenko
Anna Khristichenko
Vladimir K. LyadovVladimir K. Lyadov
Vladimir K. Lyadov
IGIvan Gaziev
Ivan Gaziev
ABAnton A. Buzdin
Anton A. Buzdin
Plasma circulating tumor DNA (ctDNA) profiling may complement tissue hotspot testing and reveal molecular changes during treatment of metastatic colorectal cancer (mCRC). We prospectively studied 39 patients with newly diagnosed unresectable mCRC receiving first-line therapy. Cell-free DNA was collected before treatment and after two and four cycles and analyzed using a 10 kb, 10-gene hybrid-capture sequencing panel with molecular barcodes and error correction. Baseline oncogenic variants were detected in 32 of 35 evaluable patients (91.4%). Compared with routine tissue PCR for shared RAS/BRAF targets, plasma testing showed 84.2% sensitivity (16/19) and 100% specificity (19/19) in the intention-to-test cohort, compared with 88.2% sensitivity (15/17) and 100% specificity (17/17) among technically evaluable samples. Three activating KRAS variants (L19F, A59T, and A146T) lay outside the tissue assays’ target regions; patients carrying these alterations received anti-EGFR therapy. Patients with metastases in two or more organs had more detectable oncogenic alterations than those with one metastatic site (median, three versus two; adjusted q = 0.00184; rank-biserial correlation = 0.687). Serial sampling revealed divergent trajectories of individual variants in nine patients. Early reductions in plasma variant allele frequencies tended to be greater among partial responders, although associations with radiological response were not significant after multiple testing correction. Compact tumor-agnostic plasma sequencing provides complementary molecular information, but its clinical utility requires further validation.

7 September 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MLM. A. Lyadova
M. A. Lyadova
OZOLEG ZAUZOLKOV
OLEG ZAUZOLKOV
JMJu. S. Mansurova
Ju. S. Mansurova
IPIlya A. Pokataev
Ilya A. Pokataev
TTT. E. Turyanskaya
T. E. Turyanskaya
КЛК. В. Лядов
К. В. Лядов
Introduction. Deficiency of the mismatch repair system (dMMR) and microsatellite instability (MSI) occur in only 4–5% of patients with metastatic colorectal cancer (mCRC), but this molecular subgroup is characterized by high sensitivity to immune checkpoint inhibitors. Data on the efficacy and safety of such therapy in the Russian population are limited, making this study relevant for real-world clinical practice. Aim. Evaluation of the efficacy and safety of immunotherapy in patients with mCRC and MSI. Materials and methods. This retrospective, multicenter, multicohort, non-randomized study included 74 patients (36 men and 38 women) aged 19 to 85 years. The median follow-up was 41.2 months. Patients received monotherapy (pembrolizumab, nivolumab) or a combination (nivolumab and ipilimumab). An objective tumor response to treatment was defined as partial or complete tumor regression. Tumor response to treatment was determined using iRECIST criteria. Results. Progression-free survival in patients with MSI-positive mCRC was 45.53 months (95% CI: 12.26 – ∞ months) in the monoimmunotherapy group and was not achieved in the combination therapy group, p < 0.05. Overall survival was 45.76 months (95% CI: 25.78 – ∞ months) in the monoimmunotherapy group and was not achieved in the combination therapy group, p < 0.05. Objective response was achieved in 18 (46%) patients in the monoimmunotherapy group and in 19 (54.30%) patients in the combination therapy group. Immune-mediated adverse events of grade 3–4 were observed only in 11 (11.86%) patients. Conclusion. The use of immunotherapy in mCRC with MSI allows achieving high rates of objective response and disease control (50% and 75.7%, respectively) with a favorable safety profile (severe complications – 11.86%).